9 research outputs found
Bismuth-based quadruple therapy following H. Pylori eradication failures: A multicenter study in clinical practice
Background & Aims: Helicobacter pylori (H. pylori) eradication in patients who failed one or more therapeutic
attempts remains challenging. This study aimed to assess the efficacy of three-in-one capsules bismuth-based
quadruple therapy (Pylera®) in these patients managed in clinical practice.
Methods: This was a prospective, open-label, multicenter study enrolling consecutive, adult patients with
persistent H. pylori infection following at least one standard therapy. All patients received a rescue quadruple
therapy with Pylera (3 capsules four times daily) and esomeprazole 20 mg (1 tablet twice daily) for 10 days.
H. pylori eradication was assessed by using Urea Breath Test 4-6 weeks following therapy ending. H. pylori
eradication rates, compliance, and side-effects were calculated.
Results: A total of 208 patients in the 9 participating centres were enrolled. Overall, 180 patients were
successfully cured from the infection, accounting for 86.5% (95% CI 81.9-91.2) and 92.3% (95% CI 88.6-96.1)
eradication rates at intention-to-treat analysis and at per protocol analysis, respectively. Cure rates were similar
across patients who failed one to three previous therapy attempts, but the success rate fell to 67% after 4 or
more therapy failures. Compliance to therapy was good in 198 (95.2%) patients, whilst in 7 (5.3%) cases the
therapy was interrupted within 5 days due to side effects. A total of 97 (46.6%) patients complained of at least
one side effect; nausea, diarrhea and vomiting were the most frequently reported.
Conclusions: Our study found that this bismuth-based quadruple therapy is highly effective as second-line
and rescue therapy for H. pylori eradication in clinical practic
Bismuth-based quadruple therapy following H. Pylori eradication failures: A multicenter study in clinical practice
Background & Aims: Helicobacter pylori (H. pylori) eradication in patients who failed one or more therapeutic
attempts remains challenging. This study aimed to assess the efficacy of three-in-one capsules bismuth-based
quadruple therapy (Pylera®) in these patients managed in clinical practice.
Methods: This was a prospective, open-label, multicenter study enrolling consecutive, adult patients with
persistent H. pylori infection following at least one standard therapy. All patients received a rescue quadruple
therapy with Pylera (3 capsules four times daily) and esomeprazole 20 mg (1 tablet twice daily) for 10 days.
H. pylori eradication was assessed by using Urea Breath Test 4-6 weeks following therapy ending. H. pylori
eradication rates, compliance, and side-effects were calculated.
Results: A total of 208 patients in the 9 participating centres were enrolled. Overall, 180 patients were
successfully cured from the infection, accounting for 86.5% (95% CI 81.9-91.2) and 92.3% (95% CI 88.6-96.1)
eradication rates at intention-to-treat analysis and at per protocol analysis, respectively. Cure rates were similar
across patients who failed one to three previous therapy attempts, but the success rate fell to 67% after 4 or
more therapy failures. Compliance to therapy was good in 198 (95.2%) patients, whilst in 7 (5.3%) cases the
therapy was interrupted within 5 days due to side effects. A total of 97 (46.6%) patients complained of at least
one side effect; nausea, diarrhea and vomiting were the most frequently reported.
Conclusions: Our study found that this bismuth-based quadruple therapy is highly effective as second-line
and rescue therapy for H. pylori eradication in clinical practic
Multifocal Gastrointestinal Angiosarcoma: a Challenging Diagnosis?
Angiosarcoma rarely involves the gastrointestinal tract. Herein, we describe the case of a 68-year-old man with haemoptysis and melena who was eventually diagnosed with multifocal angiosarcoma of the stomach, small bowel, lungs, and thyroid. The peculiarity was that the histological feature of the polypoid lesions removed at endoscopy was initially misinterpreted as benign hyperplastic polyps, whilst their neoplastic nature was clinically suspected only when the videocapsule endoscopy revealed the presence of multiple variable-sized nodules with apical erosion or active bleeding in the small bowel. Based on the very low incidence, diagnosis of angiosarcoma involving the gastrointestinal tract may be misinterpreted by both the endoscopist and pathologist
Whipple's disease: case report and review of the literature
Whipple's disease (WD) is known as an infrequent, systemic, chronic infection caused by the actinomycete Tropherima whipplei (T. whipplei). The disease is frequently characterized by a long prodromal and protean extra-intestinal phase, which often causes misdiagnosis and inappropriate treatments. Herein, we describe the case a 62-year-old man with a histological diagnosis of WD established when oral steroid treatment was started due to rheumatic manifestations, triggering intestinal symptoms. Systematic review of the literature was performed to include studies where WD was eventually diagnosed on duodenal biopsies. Three patients' subgroups were identified according to the clinical presentation
Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication
The updated Italian guidelines advise a standard 14-day triple therapy for first-line H. pylori eradication. This prospective study evaluated the cure rate following a 14-day triple therapy with either a standard or double-dose proton pump inhibitor (PPI)
Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: A prospective, randomized study
Background: Current Italian guidelines recommend 10-day bismuth-based or bismuth-free (sequential and concomitant) regimens for first-line H. pylori eradication. However, comparison among these regimens is lacking in our country. Aim: To perform a 'head-to-head' comparison among these three therapies as first-line treatment for H. pylori eradication in clinical practice. Methods: This was a prospective, open-label randomized study enrolling consecutive patients diagnosed with H. pylori infection never previously treated. Patients were randomized to receive one of the following 10-day therapies: (a) Bismuth-based therapy: esomeprazole 20. mg b.i.d and Pylera 3 tablets q.i.d; (b) Concomitant therapy: esomeprazole 20. mg plus amoxicyllin 1,000. mg, clarithromycin 500. mg and tinidazole 500. mg (all b.i.d.), and (c) Sequential therapy: esomeprazole 20. mg plus amoxicyllin 1,000. mg for 5. days followed by esomeprazole 20. mg plus clarithromycin 500. mg and tinidazole 500. mg for 5. days (all b.i.d). H. pylori eradication was assessed by using UBT 4-6 weeks after the end of therapy. Results: Overall, 187 patients were enrolled. The eradication rates achieved with Pylera, concomitant and sequential were 85.2%, 95.2%, and 93.6%, respectively, at intention to treat, and 94.5%, 96.7%, and 95.1% at per protocol analyses, without a statistically significant difference. The incidence of severe side-effects was higher with the bismuth-based therapy than with the two bismuth-free regimens (9.8% vs 1.6%; p = 0.046). Conclusions: Bismuth-based and bismuth-free therapies are equally effective for first-line H. pylori eradication. However, bismuth therapy was more frequently interrupted for side-effects than bismuth-free therapies
High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study
The prevalence of resistance to clarithromycin and metronidazole has considerably increased, with a corresponding decrease in the eradication rate for Helicobacter pylori (H. pylori) infection. Primary resistance to amoxicillin is extremely low, and esomeprazole was found to exert a noteworthy antimicrobial activity in vitro against H. pylori. A dual therapy with high-dose of esomeprazole coupled with high-dose amoxicillin might be therefore an ideal first-line treatment for H. pylori eradication. We aimed to assess the efficacy of a first-line 10-day, high-dose dual therapy consisting of amoxicillin and esomeprazole to eradicate H. pylori infection
High-dose esomeprazole and amoxicillin dual therapy for fi rst-line Helicobacter pylori eradication: a proof of concept study
Background Th e prevalence of resistance to clarithromycin and metronidazole has considerably increased, with a corresponding decrease in the eradication rate for Helicobacter pylori (H. pylori) infection. Primary resistance to amoxicillin is extremely low, and esomeprazole was found to exert a noteworthy antimicrobial activity in vitro against H. pylori. A dual therapy with high-dose of esomeprazole coupled with high-dose amoxicillin might be therefore an ideal fi rst-line treatment for H. pylori eradication. We aimed to assess the effi cacy of a fi rst-line 10-day, high-dose dual therapy consisting of amoxicillin and esomeprazole to eradicate H. pylori infection. Methods Consecutive naïve H. pylori-infected patients, who underwent an upper endoscopy in 4 Italian hospitals due to dyspeptic symptoms and found to be infected at routine histological assessment, were invited to participate. Patients enrolled received a 10-day, high-dose dual therapy comprising esomeprazole (40 mg t.i.d) and amoxicillin (1 g t.i.d.). At least 4 weeks aft er the end of the treatment a 13 C-urea breath test was performed to evaluate the eradication. Results A total of 56 patients agreed to participate in the study and were all followed-up. Th e overall eradication was 87.5% (95% CI=78.8•96.2), without a statistically signifi cant diff erence among centres. Overall, 5 (8.9%; 1.5•16.4%) patients complained of side-eff ects. Conclusions Th e 10-day, high-dose dual therapy with esomeprazole and amoxicillin might be an eff ective and safe fi rst-line regimen. Th e effi cacy of a longer 14-day regimen should be tested
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories
To date, a plenty of techniques for the detection of JAK2V617Fis used over different laboratories, with substantial differences in specificity and sensitivity. Therefore, to provide reliable and comparable results, the standardization of molecular techniques is mandatory.A network of 19 centers was established to 1) evaluate the inter- and intralaboratory variability in JAK2V617Fquantification, 2) identify the most robust assay for the standardization of the molecular test and 3) allow consistent interpretation of individual patient analysis results. The study was conceived in 3 different rounds, in which all centers had to blindly test DNA samples with different JAK2V617Fallele burden (AB) using both quantitative and qualitative assays. The positivity of samples with an AB < 1% was not detected by qualitative assays. Conversely, laboratories performing the quantitative approach were able to determine the expected JAK2V617FAB. Quantitative results were reliable across all mutation loads with moderate variability at low AB (0.1 and 1%; CV = 0.46 and 0.77, respectively). Remarkably, all laboratories clearly distinguished between the 0.1 and 1% mutated samples. In conclusion, a qualitative approach is not sensitive enough to detect the JAK2V617Fmutation, especially at low AB. On the contrary, the ipsogen JAK2 MutaQuant CE-IVD kit resulted in a high, efficient and sensitive quantification detection of all mutation loads. This study sets the basis for the standardization of molecular techniques for JAK2V617Fdetermination, which will require the employment of approved operating procedures and the use of certificated standards, such as the recent WHO 1st International Reference Panel for Genomic JAK2V617F